The firm focuses on investing in visionary founders who are leading the future of health tech and biology-driven innovation. They aim to be the first check and lead investor in disruptive companies across digital health, synthetic biology, diagnostics, 3D (bio) printing, and AI/software-enabled health tech. With a team of serial entrepreneurs and industry thought leaders, they work tirelessly to help their portfolio companies succeed. They have celebrated successful exits, including a public listing of gene therapy leader Rocket Pharma and the acquisition of Singular Bio.